Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001
An Open-label, Extension Study to Assess the Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children Who Completed the OTR3001 Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Petach Tikva, Israel, 49202
- Schneider Children Medical Center of Israel
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Children's Hospital of Alabama
-
-
California
-
Paramount, California, United States, 90723
- Bayview Research Group, LLC
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital Colorado
-
-
Florida
-
Miami, Florida, United States, 33136
- Jackson Memorial Hospital
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky
-
-
Missouri
-
St. Louis, Missouri, United States, 63141
- Mercy Clinic Children's Cancer and Hematology Center
-
-
New York
-
New York, New York, United States, 10016
- New York University Langone Medical Center
-
Stony Brook, New York, United States, 11794
- Stony Brook University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Presbyterian Blume Pediatric Hematology & Oncology Clinic
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Akron Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- The Children's Hospital at Oklahoma University Medical Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Monroe Carell Jr. Children's Hospital at Vanderbilt
-
-
Texas
-
Dallas, Texas, United States, 75235
- Children's Medical Center of Dallas
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria include:
- Male and female patients aged 6 to 17 years, inclusive, who completed the 4-week study drug treatment in study OTR3001 and who, based on the investigator's judgment, will benefit from continuing treatment with oxycodone HCl CR 20 to 240 mg/day for the management of moderate to severe malignant or nonmalignant pain;
- Patients must have tolerated the oxycodone HCl CR therapy in OTR3001 as demonstrated at the start of the study;
- Patients must be willing and able to swallow the oxycodone HCl CR tablets whole.
Exclusion Criteria include:
- Patients with ongoing adverse events in OTR3001 that, in the investigator's opinion, disqualify them from participation in the study;
- Female patients who are pregnant or lactating;
- Patients requiring opioid at doses equivalent to < 20 mg/day or > 240 mg/day oxycodone for treatment of their malignant or nonmalignant pain;
- Patients who are allergic to oxycodone or have a history of allergies to other opioids (this criterion does not include patients who have experienced common opioid side effects [eg, nausea, constipation]);
- Patients who are contraindicated for the use of opioids;
- Patients who are currently being maintained on methadone for pain;
- Patients who have an abnormality on vital signs, physical examination, or laboratory testing significant enough that the investigator deems the patient is not appropriate for the study;
- Patients who have any planned surgery during the course of the study, with the exception of the placement of central or peripheral venous access devices;
- Patients currently taking an investigational medication/therapy other than the study drug (oxycodone HCl CR) at the start of screening or during the study.
Other protocol specific inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Oxycodone HCl controlled-release
Oxycodone hydrochloride controlled-release tablets
|
Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Number of Participants With Adverse Events as a Measure of Safety.
Time Frame: Up to 6 months (during the study) and 7-10 days poststudy (safety follow-up assessment).
|
Safety assessments included adverse events (AEs), vital sign measurements, clinical laboratory test results, and somnolence (University of Michigan Sedation Scale [UMSS]).
Safety variables were summarized descriptively within age group for the extension safety population.
|
Up to 6 months (during the study) and 7-10 days poststudy (safety follow-up assessment).
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OTR3002
- 2011-002235-26 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.